Cargando…

Dulaglutide‐combined basal plus correction insulin therapy contributes to ideal glycemic control in non‐critical hospitalized patients

AIMS/INTRODUCTION: We investigated whether dulaglutide (DU)‐combined conventional insulin therapy is beneficial for glycemic control in non‐critically ill hospitalized patients with type 2 diabetes. MATERIALS AND METHODS: This study was a prospective, randomized controlled pilot study. Participants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fushimi, Nobutoshi, Shibuya, Takashi, Yoshida, Yohei, Ito, Shun, Hachiya, Hiroki, Mori, Akihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944833/ https://www.ncbi.nlm.nih.gov/pubmed/31168938 http://dx.doi.org/10.1111/jdi.13093

Ejemplares similares

Investigating the Relationship between Morning Glycemic Variability and Patient Characteristics Using Continuous Glucose Monitoring Data in Patients with Type 2 Diabetes
por: Takeishi, Soichi, et al.
Publicado: (2017)

Hypoglycemia and glycemic variability are associated with mortality in non‐intensive care unit hospitalized infectious disease patients with diabetes mellitus
por: Takeishi, Soichi, et al.
Publicado: (2015)

Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring
por: Takeishi, Soichi, et al.
Publicado: (2015)

Major Increases between Pre- and Post-breakfast Glucose Levels May Predict Nocturnal Hypoglycemia in Type 2 Diabetes
por: Takeishi, Soichi, et al.
Publicado: (2016)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study
por: Yoshiji, Satoshi, et al.
Publicado: (2022)

The role of sulfonylurea plus basal insulin on glycemic variability compared to basal bolus regime in T2D patients
por: Freire, Paula Vieira, et al.
Publicado: (2015)

Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study
por: Hoog, Meredith, et al.
Publicado: (2023)

The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes
por: Ruda, Alexandru Ioan, et al.
Publicado: (2023)

Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
por: Ito, Hiroyuki, et al.
Publicado: (2014)

Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study
por: Batule, Sol, et al.
Publicado: (2022)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

l-Menthol sprayed on gastric mucosa causes edematous change
por: Mori, Akihiro, et al.
Publicado: (2014)

In search of the ideal basal insulin: Does the new‐generation ultra‐long‐acting insulin, degludec, provide the answer?
por: Hui, Elaine, et al.
Publicado: (2013)

Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
por: MacIsaac, Richard J.
Publicado: (2020)

Differences in Glycemic Control in Diabetic and Non-diabetic Patients with Parenteral Nutrition Using a Basal plus Correction Insulin Regimen: An Observational, Retrospective Study
por: Ramos, Analía, et al.
Publicado: (2018)

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes
por: Huang, Jinxin, et al.
Publicado: (2023)

Development of an external-to-internal convertible endoscopic biliary drainage device – a preliminary prospective feasibility study
por: Mori, Akihiro, et al.
Publicado: (2018)

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes
por: Lingvay, Ildiko, et al.
Publicado: (2022)

The effect of Insulin Degludec on glycemic control in diabetic cats over a 12-month period
por: ODA, Hitomi, et al.
Publicado: (2020)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
por: Giugliano, Dario, et al.
Publicado: (2021)

Necrotizing Pancreatitis Secondary to Dulaglutide Use
por: Bhat, Salman Zahoor, et al.
Publicado: (2021)

Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study
por: Mody, Reema, et al.
Publicado: (2019)

Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin
por: Uchinuma, Hiroyuki, et al.
Publicado: (2020)

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
por: Kim, Youngsook, et al.
Publicado: (2022)

Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus
por: Chien, Ming‐Nan, et al.
Publicado: (2016)

Reconsidering the Basal Proportion of Insulin Dose: Glycemic and Microvascular Outcomes in Type 1 Diabetes Mellitus
por: Pozos-Varela, Francisco Javier, et al.
Publicado: (2021)

Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better
por: Sanada, Junpei, et al.
Publicado: (2021)

Randomized Study Comparing a Basal-Bolus With a Basal Plus Correction Insulin Regimen for the Hospital Management of Medical and Surgical Patients With Type 2 Diabetes: Basal Plus Trial
por: Umpierrez, Guillermo E., et al.
Publicado: (2013)

Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen
por: Onishi, Yukiko, et al.
Publicado: (2020)

Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen
por: Lin, Yi-Hsuan, et al.
Publicado: (2022)

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
por: Jang, Han Na, et al.
Publicado: (2019)

Mode of administration of dulaglutide: implications for treatment adherence
por: Amblee, Ambika
Publicado: (2016)

Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes
por: Wang, Rijun, et al.
Publicado: (2021)

Exacerbation of atrial fibrillation related to dulaglutide use
por: Lee, Jayden, et al.
Publicado: (2021)

A Case of Dulaglutide-Induced Vaginal Bleed
por: Vaccaro, Christopher J, et al.
Publicado: (2023)

Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen
por: Seufert, Jochen, et al.
Publicado: (2019)

Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
por: Ruan, Zhen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0pnr3mlgnuobmj535hcdf139lr